Ethynyl Derivatives as mGluR5 Negative Allosteric Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds targeting metabotropic glutamate receptors, specifically mGluR5, either act as positive allosteric modulators increasing receptor activity or are ineffective as negative allosteric modulators, failing to provide a reduction in receptor activation for treating conditions like anxiety, pain, and neurological disorders effectively.
Innovation Solution
Development of ethynyl derivatives of formula I, which act as potent negative allosteric modulators (NAMs) of the mGluR5 receptor, reducing receptor activation and offering therapeutic benefits for anxiety, pain, and various neurological disorders, unlike traditional positive allosteric modulators.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are designed as positive allosteric modulators of mGluR5, then receptor activity is increased, but this cannot achieve the desired therapeutic effect for conditions requiring reduction of receptor activation
Solution Approach 1:
The patent inverts the conventional approach by designing compounds that act as negative allosteric modulators (NAMs) instead of positive allosteric modulators (PAMs). This inversion of the modulatory effect transforms the pharmacological action from increasing to decreasing receptor activation, thereby achieving therapeutic effectiveness for conditions where reduction of mGluR5 activity is required.
Solution Approach 2:
The patent changes the key pharmacological parameter from positive modulation to negative modulation of the mGluR5 receptor. By altering the direction of allosteric modulation, the compounds achieve a reversal in receptor activation effects, enabling therapeutic intervention in disorders characterized by excessive glutamatergic transmission.
2Reliability
If traditional mGluR5 modulators are used, then receptor binding is achieved, but they fail to provide effective negative allosteric modulation
Solution Approach 1:
The patent applies local quality by introducing specific structural features (ethynyl group at position 2, fluorine substitution patterns) that confer negative allosteric modulation capability to the imidazopyridine core. These localized structural modifications enable the compounds to bind to a specific allosteric site on mGluR5 and induce a conformational change that reduces receptor activation, rather than simply competing for the orthosteric site.
Solution Approach 2:
The patent creates composite molecular structures by combining the imidazopyridine core with ethynyl-phenyl or ethynyl-thiophenyl substituents and fluorine atoms at specific positions. This composite structure integrates multiple functional elements that work synergistically to achieve potent negative allosteric modulation, combining receptor binding affinity with the ability to induce inhibitory conformational changes.
Data Source
AI summary
The present invention relates to ethynyl derivatives of formula Iwith variables as defined herein, or to a pharmaceutically acceptable acid addition salt thereofCompounds of formula I are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of, e.g., anxiety and pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).